RhoGEF^Pbl controls anillin-GFP localization during anaphase via F-actin– and myosin II–dependent and –independent mechanisms. (A–H) Frames from time-lapse sequences of anillin-GFP cells progressing through anaphase/telophase (single Z sections, except for D, G, and H, which are projections of five sections). (A) A control cell showing the normal redistribution of anillin-GFP (see Video 1, available). (B) A cell after 3 d of RhoGEF^Pbl RNAi (see Video 2). (C) A cell after 1-μg/ml LatA treatment (surface Z section; see Video 3). (D) The same as C but the LatA was washed out at 10 min, soon after the formation of anillin-GFP structures (see Video 4). (E) A cell after 3 d of RhoGEF^Pbl RNAi and LatA combined. (F) A cell after 3 d of MRLC^Sqh RNAi (see Video 5). (G) A cell after MRLC^Sqh RNAi and LatA combined. (H) A cell after 4 d of Dia and Rok RNAi and LatA treatment combined. (I) A LatA-treated anillin-GFP cell fixed during anaphase/telophase and labeled with a Rho1 antibody (red in merged; max intensity projection). (A', B', and F') semiquantitative measurements of the mean anillin-GFP intensities at the equator (□) and poles (◊), expressed as arbitrary units (AU) relative to time 0 (metaphase/anaphase [M/A]) in control, Pbl, and Sqh RNAi cells, shown for three cells each (different colors represent different cells). Times are h:min:s from anaphase onset. Bars, 5 μm.